Lorlatinib Patent Expiration
Lorlatinib is Used for treating adult patients with metastatic non-small cell lung cancer (NSCLC) that is anaplastic lymphoma kinase (ALK)-positive. It was first introduced by Pfizer Inc
Lorlatinib Patents
Given below is the list of patents protecting Lorlatinib, along with the drug name that holds that patent and the company name owning that drug.
| Drug Used in | Drug Patent Number | Drug Patent Title | Drug Patent Expiry | Drug Owner |
|---|---|---|---|---|
| Lorbrena | US11299500 | Crystalline form of lorlatinib free base hydrate | Oct 04, 2038 | Pfizer |
| Lorbrena | US10420749 | Crystalline form of lorlatinib free base | Jul 27, 2036 | Pfizer |
| Lorbrena | US11020376 | Crystalline form of lorlatinib free base | Jul 27, 2036 | Pfizer |
| Lorbrena | US8680111 | Macrocyclic derivatives for the treatment of diseases | Mar 05, 2033 | Pfizer |
Lorlatinib's Family Patents
Explore Our Curated Drug Screens
Clinical Trials
Recent Clinical Trials on Lorlatinib:
Sometimes companies keep conducting clinical trials even after the drug's approval to discover new formulations, methods of use, or new treatment indications, so they could file for additional patents or receive regulatory exclusivity extensions, such as pediatric exclusivity, potentially delaying generic competition. Based on these recent clinical trials, generic companies need to consider the potential for new intellectual property or regulatory hurdles. These strategic moves by the drug owner might delay generic substitution or lead to additional sales of the brand drug, even after patent expiry.
